Plain-English translation of NCT06947941 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called + can help reduce psychotic symptoms—such as hallucinations, delusions, and confusion—that sometimes develop in people with Alzheimer's disease. About 325 people will participate. Half will receive the medication and half will receive a placebo (an inactive pill that looks identical), and neither participants nor the research team will know which group each person is in until the study ends.
Some people with Alzheimer's disease develop psychotic symptoms like seeing or hearing things that aren't there, or believing false things. Current treatments don't work well for everyone and can have serious side effects. This medication is being tested to see if it offers a safer and more effective option.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication or a placebo, and neither you nor your doctor will know which one you're getting. You'll take the treatment by mouth and visit the research clinic regularly so the team can monitor how well the medication works and check for any side effects. The study involves physical exams, blood tests, and assessments of your symptoms over several months.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States